Press Releases – NASDAQ (US) Website

Press Releases

Aug 09, 2022
BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular Cancer    read more...
Aug 04, 2022
BeiGene Reports Second Quarter 2022 Financial Results    read more...
Jul 14, 2022
BeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for PD-1 Inhibitor Tislelizumab in 2L ESCC    read more...
Jul 13, 2022
BeiGene Appoints Chan Lee as General Counsel    read more...
Jul 06, 2022
BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies    read more...
Jun 30, 2022
BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma    read more...
Jun 21, 2022
BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab    read more...
Jun 13, 2022
BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets    read more...
Jun 13, 2022
BeiGene Announces PDUFA Goal Date Extension for U.S. sNDA for BRUKINSA for the Treatment of CLL/SLL    read more...
Jun 10, 2022
China NMPA Approves Tislelizumab for Recurrent or Metastatic Nasopharyngeal Cancer    read more...
Jun 10, 2022
BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at European Hematology Association 2022 Congress    read more...
Jun 08, 2022
BeiGene to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference    read more...
May 26, 2022
BeiGene Clinical Data Presentations at 2022 ASCO Annual Meeting Demonstrate Mature and Growing Oncology Portfolio    read more...
May 17, 2022
BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Switzerland    read more...
May 12, 2022
BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hematology Association 2022 Congress    read more...
May 05, 2022
BeiGene Reports First Quarter 2022 Financial Results    read more...
May 04, 2022
BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)    read more...
Apr 29, 2022
BeiGene Breaks Ground on New Manufacturing and Clinical R&D Center at the Princeton West Innovation Campus in New Jersey    read more...
Apr 28, 2022
BeiGene Announces BRUKINSA (zanubrutinib) Approval in Uruguay in Mantle Cell Lymphoma, Marginal Zone Lymphoma, and Waldenström’s Macroglobulinemia    read more...
Apr 27, 2022
BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual Meeting    read more...